|
|
|
|
| LEADER |
05183cam a2200649 a 4500 |
| 001 |
c000405113 |
| 003 |
CARM |
| 005 |
20200427160144.0 |
| 008 |
200427s2004 gw b 001 0 eng |
| 010 |
|
|
|a 2003070423
|
| 015 |
|
|
|a GBA3T6800
|2 bnb
|
| 016 |
7 |
|
|a 101211407
|2 DNLM
|
| 016 |
7 |
|
|a 009728450
|2 Uk
|
| 019 |
1 |
|
|a 25198533
|z 26314047
|5 LACONCORD2021
|
| 020 |
|
|
|a 3540407170 (alk. paper)
|
| 035 |
|
|
|a (OCoLC)53953521
|5 LACONCORD2021
|
| 040 |
|
|
|a DLC
|b eng
|c DLC
|d NU
|
| 042 |
|
|
|a pcc
|
| 043 |
|
|
|a e-sz---
|
| 050 |
0 |
0 |
|a HD9665.5
|b .G37 2004
|
| 060 |
0 |
0 |
|a 2004 D-573
|
| 060 |
1 |
0 |
|a QV 736
|b G253L 2004
|
| 082 |
0 |
0 |
|a 338.4/76151
|2 22
|
| 084 |
|
|
|a 85.15
|2 bcl
|
| 100 |
1 |
|
|a Gassmann, Oliver,
|d 1967-
|
| 245 |
1 |
0 |
|a Leading pharmaceutical innovation :
|b trends and drives for growth in the pharmaceutical industry /
|c Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz.
|
| 260 |
|
|
|a Berlin ;
|a New York :
|b Springer,
|c 2004.
|
| 300 |
|
|
|a xi, 178 p. :
|b ill., maps. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|a Machine derived contents note: S nnov ation as a Key Success Factor in the Pharmaceutal -- Industry -- The Productvity aradox -- The Blockbuster Imperative 5 -- Strategies or Growth 10 -- Do You Want to Be in This Industry? 13 -- Bargaining Power of Suppliers 15 -- Bargaining Pow er f uyers 15 -- Risk of Entry from P ential Com titors -- Threat of Substitute Products 17 -- R egulative Forces 17 -- Rivalry a on Esablished C mpanies -- Entering the Market Quickly 20 -- C on clu sion s 21 -- II Pharmaceutical nnovatio Teas Swi d 23 -- Largest Eco rnic Value-Added of GDP in Switzerland 23 -- Stable M arket G row th 25 -- Sound Productivity an Employment 30 -- Strong Support by Industry Associations 31 -- H ighly G lobal O rientation 33 -- CIomplx Industry and Product Classification -- ragnimnted Market Structure. 39 -- Sonioine d Fi nancing Systems 43 -- Strict New D rug Registration 44 -- A ccurate Price Regulation 50 -- III. The Science and Technology Chaenge: Ho to d Ne --
|
| 505 |
0 |
0 |
|a Drugs 53 -- Rise of the Biotechnology Industry: Boosting Innovation. 53 -- High Throughput Screening Fail Earlier, Succeed Sooner, 5 -- Combinatorial Chemistry: Cut Experimental Cycle Times -- Bioinformatics: More than 100 Gigabyte of Data pe Day 60 -- Proteonmics: Profiting l rio the Human Genome Project -- Genomics: Towards Individualization and Mass Castomizati 6 -- Pharmacogenorics: Create Tailormade Drugs -- Molecular Design: From Experimenting to Analyt ic esgn 67 -- C onclusions 68 -- IV The Pipeline Managemen Chalenge: How to Shape the -- nnovation Flow -- The Importance of Pipeline Management -- The Complexity of Drug Discover 75 -- The Diftrent Phases of the R&D Process -- The R&D Process at HoffmannLa Roche -- C onclusions 85 -- V I The Outsorcing and nternationalization Chaenge: t -- Harness Outside nnovation 87 -- Impact o OOtsourcig on the Pharmaceutical Value Chain 87 -- Successful (ommercialization of a BreakFlhough Technology 9 --
|
| 505 |
0 |
0 |
|a Trends and Drivers of Internationalization 9 -- R&D Internationalization of Swiss Pharmaceutical Companies.. 102 -- Locations of Pharmaceutical R&D Abroad 10 -- Thre Prinipal Puoblens of Internationa R&D 10 -- VI Management Answers t Pharmaceutica R&D Chalet 117 -- Managing the Research-to-Dev eopmeg Handover. 117 -- Managing Human Resources 119 -- Managing Projects and the Portfolio -- Managing Outsourcing Activities -- Managing Intellectual Property Rights 127 -- Managing R&D S trategy at Schering 131 -- Managing Virtual Project Management Pools a Roche 33 -- Managing Uncertainty at Roche 135 -- Managing Know-how Transfer at Kao 136 -- Conclusions 137 -- SVI. Future Directions and T rends 139.
|
| 650 |
1 |
2 |
|a Drug Industry
|x organization & administration.
|
| 650 |
2 |
2 |
|a Research
|x organization & administration.
|
| 650 |
2 |
2 |
|a Technology, Pharmaceutical.
|
| 650 |
2 |
2 |
|a Organizational Innovation.
|
| 650 |
2 |
2 |
|a Pharmacology, Clinical.
|
| 650 |
|
7 |
|a Drugs
|x Research
|x Management.
|2 fast
|
| 650 |
|
7 |
|a Pharmaceutical industry
|x Technological innovations.
|2 fast
|
| 650 |
|
0 |
|a Pharmaceutical industry
|x Technological innovations.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|x Technological innovations
|z Switzerland
|v Case studies.
|
| 650 |
|
0 |
|a Drugs
|x Research
|x Management.
|
| 650 |
|
0 |
|a Drugs
|x Research
|z Switzerland
|x Management
|v Case studies.
|
| 651 |
|
7 |
|a Switzerland.
|2 fast
|
| 655 |
|
7 |
|a Case studies.
|2 fast
|
| 700 |
1 |
|
|a Zedtwitz, Maximilian von,
|d 1969-
|
| 700 |
1 |
|
|a Reepmeyer, Gerrit,
|d 1976-
|
| 852 |
8 |
|
|b CARM
|i C13784
|p 0655773
|f BK
|
| 852 |
8 |
|
|b SCAN
|h A3:AF08G0
|i C13784
|p 0655773
|f BK
|
| 852 |
8 |
|
|b SCAN
|h A3:AF08G0
|i C13784
|p 0655773
|f BK
|
| 856 |
4 |
1 |
|3 Table of contents only
|u http://www.loc.gov/catdir/toc/fy0705/2003070423.html
|
| 999 |
f |
f |
|i abdefd33-2d00-572b-95c8-e967885407a4
|s 5f5d9818-9da4-5706-9834-0dde9611f0b5
|
| 952 |
f |
f |
|p Can circulate
|a CAVAL
|b CAVAL
|c CAVAL
|d CARM 1 Store
|e C13784
|h Other scheme
|i book
|m 0655773
|
| 952 |
f |
f |
|a CAVAL
|b CAVAL
|c CAVAL
|d Unmapped Location
|e C13784
|f A3:AF08G0
|h Other scheme
|